At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer(Memorial Sloan Kettering Cancer Center), Craig B. Thompson(Memorial Sloan Kettering Cancer Center)
Cited by 377
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
|Journal of Clinical Investigation|2007|1.1k
Tumor suppressors and cell metabolism: a recipe for cancer growth
|Genes & Development|2009|1.1k